To include your compound in the COVID-19 Resource Center, submit it here.
FDA removed the REMS for rosiglitazone-containing Type II diabetes drugs. The move comes 5 years after FDA issued the REMS
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury